PTO/SB/08a (07-05)

Approved for use through 07/31/2006, OMB 0651-0031

Under the Paperwork Reduction Act of 1995.	. no pen	sons are required to res		on unless it contains a valid OMB control nu	
Substitute for form 1449A/PTO				mplete if Known	
		,	Application Number	10/661,780	
INFORMATION DISC	CLO	SURE	Filing Date	09/15/2003	
STATEMENT BY AP			First Named Inventor	PHILIPPE BOUCHARD	
• · · · · · · · · · · · · · · · · · · ·		-,	Art Unit	1614	
(Use as many sheets as nec	cessary	,	Examiner Name	Brian Yong S. Kwon	
Chart 1	of	3	Attorney Docket Number	098501-0305998	

U. S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number Number-Kind Code <sup>2 (I known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
/B.K./ -/B.K./		l <sup>us-</sup> 6.077.523	06/20/2000	Romano Deghenghi			
7D.N.7		us- 6,022,860	02/08/2000	Engel et al.			
MILLION S MARIE AND IT AND		US-					
PARAMETER CHANGE A COLO		US-					
		US-	**************************************				
		US-	and the state of t				
		US-		The state of the s	gaaran aan aan aan aan aan aan aan aan aa		
polymous, in proping a son topic grip market as		US-	· · · · · · · · · · · · · · · · · · ·				
		US-	*))				
		US-		Part & Art Hill German and in Section was because in an extension of the community of the section and the sect			
	Francis Martin Britis I I I I	US-		The second secon			
i beddings or n. 1. "I begging on 1 even		US-	and were free from the constraint and a second seco	AND THE RESIDENCE OF THE PROPERTY OF THE PROPE	Andreas and an action of the second s		
		US-					
		US-		Marian - Ma			
or any grammer consignment of the		US-		materia de començão de Cardina e Colonia do 100 de	Marie Control of the		
North Congression in Street and		US-		AMERICAN LAPER LAPER LAPER OF THE PROPERTY OF	gaggangga vir mangagganggangganggan paguron syam socialada diralad keristi sari dabid (dabid) damiseri (1989) hid (1989) hid (1989)		
	POLICY STANOOT LANSSTON	US-					
	************	US-		мада. Тор <sub>унда</sub> -да и на моруууша из эки обхододо такатия масанала ин на починалага и починалага на починалага и от че			

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> 'Number <sup>4</sup> 'Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	₩6				
**************			***************************************	43 44 74 144 144 144 144 144 144 144 144 1	######################################					
W 67340341 V FFLARAG 1 V	94444		***************************************	***************************************	4 10 6 1 7 2 2 2 4 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1					
	*********	331 444 3 3 3 3 4 4 4 4 4 4 4 4 4 4 4 4	#N7 1.104.EP#H2144.P4 E7# 3#11 G P#7#0#14	vp.1+12.00041.me.me.14.938.p.14.p.42.pp#+++++++++++++++++++++++++++++++++++	21 - P\$P\$-2-4-past (\$444 - p. 19574-4-5759 P\$ 4.64-7-19-6-5864					
***************************************			7907-4444	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	*   *   *   *   *   *   *   *   *   *					

	programment communications and the second of	l Date	
Examiner		Date	
Signature		Considered	
	1	i	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 

1 Applicant's unique citation designation number (optional). 
2 See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspie.gov">www.uspie.gov</a> or MPEP 901.04. 
3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 

4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 

5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 

6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b (07-05)

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute fo	r form 1449B/PTO			Complete if Known		
				Application Number	10/661,780	
INFO	RMATION DI	SCLO	SURE	Filing Date	09/15/2003	
STAT	EMENT BY	APPLI	CANT	First Named Inventor	PHILIPPE BOUCHARD	
•				Art Unit	1614	
	(Use as many sheets as	s necessary,	)	Examiner Name	Brian Yong S. Kwon	
Sheet	2	of	3	Attorney Docket Number	098501-0305998	

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
		NESTOR, JR. ET AL., "Potent gonadotropin releasing hormone antagonists with low histamine-releasing activity," J. Med. Chem., Institute of Bio-Organic Chemistry, Vol. 35 (No. 21), p. 3942-3948, (October 16, 1992).	,				
		DEGHENGHI ET AL., "Antarelix (EP 24332) a novel water soluble LHRH antagonist," Biomed. Pharmacother., Europeptides (Argenteuil, France), Vol. 47 (No. 2-3), p. 107-110, (1993).					
		RIVIER ET AL., "Gonadotropin-releasing hormone antagonists with N omega-triazolylornithine, -lysine, or -p-aminophenylalanine residues at positions 5 and 6," J. Med. Chem., Salk Institute for Biological Studies (La Jolla, California), Vol. 35 (No. 23), p. 4270-4278, (November 13, 1992).					
	See Attachm 1						
***************************************		HAVIV ET AL., "In vitro and in vivo activities of reduced-size antagonists of luteinizing hormone-releasing hormone," J. Med. Chem., TAP Pharmaceuticals, Inc. (Abbott Park, IL), Vol. 37 (No. 5), p. 701-705, (March 4, 1994).	,,,,,,,,,,				
		WEINBAUER ET AL., "Comparison of the antigonadotropic activity of three GnRH antagonists (Nal-Glu, Antide and Cetrorelix) in a non-human primate model (Macaca fascicularis)," Andrologia, Institute of Reproductive Medicine of the University (Munster, Germany), Vol. 25 (No. 3), p. 141-147, (May-June 1993).	** ******				
yddays 1,5 yg (yoʻsiaalivinday).k							
****************	g profiter to the first of the						

Examiner Signature	/Brian-Yong Kwon/	Date Considered	02/15/2008

<sup>\*</sup>EXAMINER; Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## Addendum

## Page 3 of 3

## Attachment 1

a.

b. STOECKEMANN ET AL., "Effects of the luteinizing-hormone-releasing hormone (LHRH) antagonist ramorelix (hoe013) and the LHRH agonist buserelin or dimethylbenz[]anthrracene-induced mammary carcinoma: studies with slow-release formulations," J. Cancer Res. Clin. Oncol., Hoechst AG, Pharma-Research (Frankfurt/Main, Germany), Vol. 119 (No. 8), p. 457-462, (1993).

c.

/Brian-Yong Kwon/

02/15/2008